Dianne M. Nast

Dianne Nast has extensive and diverse experience in pharmaceutical litigation and antitrust litigation, and much of her professional career has been dominated by this type of litigation. With over 25 years in this field, she is consistently recognized by her clients and peers as one of the best lawyers in the country.
The National Law Journal selected Ms. Nast as one of the nation’s top fifty women litigators. She has been included in The Best Lawyers in America since 2003, and she has repeatedly been named by Philadelphia Magazine as one of Pennsylvania’s top fifty women attorneys. She has been selected as a Super Lawyer every year for more than a decade, and has earned an AV rating in the prestigious Martindale Hubbell lawyer rankings.

A Leader in Antitrust Litigation

Ms. Nast has served as lead or co-lead counsel in many large antitrust cases including Augmentin Antitrust Litigation (E.D. Va.), Wellbutrin SR Antitrust Litigation (E.D.Pa.), Paxil Antitrust Litigation (E.D. Pa.) and Nifedipine Antitrust Litigation (D.D.C.).

Ms. Nast currently serves as a member of the Executive Committee in multiple antitrust cases, including In re: Effexor XR Antitrust Litigation (D. N.J.); Modafinil Antitrust Litigation (E.D. Pa.); and In Skelaxin Antitrust Litigation (E.D. Tenn.).

Experienced Dangerous Drug Lawyer

Ms. Nast has taken active roles in numerous cases and is frequently asked to take a leadership role in the resolution of those cases. Ms. Nast currently holds court-appointed leadership roles in several major pharmaceutical cases including co-lead counsel in Zoloft SSRI Birth Defect Litigation, federal state liaison and steering committee member in Avandia product liability litigation, and co-lead counsel in Philadelphia and federal state liaison committee in Yasmin/Yaz product liability litigation. Ms. Nast has also been appointed to the Executive Committee in the Effexor MDL litigation in the Eastern District of Pennsylvania.

She has held court-appointed leadership roles and helped achieve multi-million dollar settlements in many major lawsuits including:

Diet Drugs Litigation, (E.D.P.A.), MDL. No. 1203, which settled at an estimated $6.44 billion.
Serzone Products Liability Litigation, (S.D.W.V.), MDL No. 1477, which resulted in a $70 million settlement.
Factor Concentrate Litigation, (N.D. Ill.), MDL No. 986, a case that settled for in excess of $600 million.

Serving the Community

Within her community, Ms. Nast is President of the Center for Research for Women and Newborn Health (“CROWN”). She also served for ten years on two Boards of Education, coached two Quiz Bowl teams for almost a decade and mentored hundreds of high school students in Science Fairs throughout the United States.